Zevra’s Arimoclomol Brings Efficacy Questions To First Genetic Metabolic Diseases Adcomm
Executive Summary
The US FDA seeks input on the validity of the clinical outcome scale used in the sole pivotal trial, whether treatment benefit can be ascertained, and the robustness of the confirmatory evidence in Niemann-Pick disease type C.